Wedbush Reduces Earnings Estimates for Aclaris Therapeutics

Key Points

• Wedbush analysts have lowered their FY2026 earnings per share estimate for Aclaris Therapeutics to ($0.53), reflecting a pessimistic outlook on the company.
• Despite the lowered EPS forecast, Wedbush maintains an "Outperform" rating with an $8.00 price target, while the consensus estimate is ($0.82) per share.
• The stock has seen mixed reviews from analysts, with one sell rating, eight buy ratings, and an average price target of $8.71 indicating a consensus rating of "Moderate Buy."

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at Wedbush reduced their FY2026 earnings per share estimates for shares of Aclaris Therapeutics in a report issued on Wednesday, July 30th. Wedbush analyst M. Fan now forecasts that the biotechnology company will post earnings of ($0.53) per share for the year, down from their previous estimate of ($0.52). Wedbush currently has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share.

Other equities analysts have also issued reports about the company. Scotiabank decreased their price objective on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating for the company in a research report on Friday, May 9th. Piper Sandler initiated coverage on Aclaris Therapeutics in a research report on Thursday, July 10th. They set an "overweight" rating and a $6.00 price target for the company. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, June 25th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $8.71.

Aclaris Therapeutics Stock Down 1.0%

Shares of ACRS traded down $0.02 on Friday, hitting $1.55. The company's stock had a trading volume of 265,183 shares, compared to its average volume of 984,147. The firm's fifty day moving average price is $1.52 and its 200-day moving average price is $1.64. Aclaris Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $5.17. The firm has a market capitalization of $167.29 million, a price-to-earnings ratio of -1.11 and a beta of 0.30.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative return on equity of 30.73% and a negative net margin of 732.42%.

Institutional Investors Weigh In On Aclaris Therapeutics

Large investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP bought a new stake in Aclaris Therapeutics in the 4th quarter valued at $26,000. Invesco Ltd. bought a new position in Aclaris Therapeutics during the 4th quarter worth $28,000. Graham Capital Management L.P. bought a new position in Aclaris Therapeutics during the 4th quarter worth $35,000. Commonwealth Equity Services LLC bought a new position in Aclaris Therapeutics during the 4th quarter worth $36,000. Finally, Alpine Global Management LLC bought a new position in Aclaris Therapeutics during the 4th quarter worth $38,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.